ArticleFrontiers in oncology2019

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.

Hideaki Abe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.